Compare AUPH & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | INDV |
|---|---|---|
| Founded | 1993 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 4.7B |
| IPO Year | 2014 | 2014 |
| Metric | AUPH | INDV |
|---|---|---|
| Price | $16.17 | $34.58 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | 921.0K | ★ 1.8M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5075.00 | ★ 8100.00 |
| EPS | 0.53 | ★ 1.67 |
| Revenue | $283,055,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | $30.66 | ★ $20.82 |
| Revenue Growth | ★ 20.38 | 4.29 |
| 52 Week Low | $10.34 | $22.22 |
| 52 Week High | $19.25 | $42.81 |
| Indicator | AUPH | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 31.88 |
| Support Level | $15.55 | $32.06 |
| Resistance Level | $16.40 | $35.54 |
| Average True Range (ATR) | 0.38 | 0.96 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 13.95 | 10.04 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).